Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia

[1]  K. Hajjar,et al.  Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.

[2]  E. Plow,et al.  Lp(a): An Interloper into the Fibrinolytic System? , 1990, Thrombosis and Haemostasis.

[3]  H. Arnesen,et al.  Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction , 1990, Thrombosis and Haemostasis.

[4]  M. Cassader,et al.  Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. , 1988, Atherosclerosis.

[5]  R. D'Agostino,et al.  Fibrinogen and risk of cardiovascular disease. The Framingham Study. , 1987, JAMA.

[6]  G. Franceschini,et al.  Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. , 1987, The Journal of laboratory and clinical medicine.

[7]  L Wilhelmsen,et al.  Analysis of risk factors for stroke in a cohort of men born in 1913. , 1987, The New England journal of medicine.

[8]  S. Humphries,et al.  ROLE OF GENETIC VARIATION AT THE FIBRINOGEN LOCUS IN DETERMINATION OF PLASMA FIBRINOGEN CONCENTRATIONS , 1987, The Lancet.

[9]  P. A. Todd,et al.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. , 1987, Drugs.

[10]  T. Saldeen,et al.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. , 1987, Journal of the American College of Cardiology.

[11]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[12]  T. Kjellström,et al.  The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. , 1986, Atherosclerosis.

[13]  N. Rifai,et al.  Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. , 1986, Clinical chemistry.

[14]  M. Kameyama,et al.  Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. , 1986, Atherosclerosis.

[15]  M. Blombäck,et al.  Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.

[16]  H. Schulte,et al.  Epidemiological Study on Factor VII, Factor VIII and Fibrinogen in an Industrial Population: I. Baseline Data on the Relation to Age, Gender, Body-Weight, Smoking, Alcohol, Pill-Using, and Menopause , 1985, Thrombosis and Haemostasis.

[17]  C. Sirtori,et al.  Increased platelet sensitivity and thromboxane B2 formation in type‐II hyperlipoproteinaemic patients , 1984, European journal of clinical investigation.

[18]  L. Wilhelmsen,et al.  Fibrinogen as a risk factor for stroke and myocardial infarction. , 1984, The New England journal of medicine.

[19]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[20]  C. Forbes,et al.  INCREASED BLOOD VISCOSITY AND FIBRINOLYTIC INHIBITOR IN TYPE II HYPERLIPOPROTEINAEMIA , 1982, The Lancet.

[21]  J. Stuart,et al.  Haematological stress syndrome in atherosclerosis. , 1981, Journal of clinical pathology.

[22]  G. Vilaire,et al.  Exposure of platelet fibrinogen receptors by ADP and epinephrine. , 1979, The Journal of clinical investigation.

[23]  G. Dahlén,et al.  Lp(a) lipoprotein/pre‐ß1‐lipoprotein in Swedish middle‐aged males and in patients with coronary heart disease , 1975, Clinical genetics.

[24]  J. Caen,et al.  An Abnormal Platelet Glycoprotein Pattern in Three Cases of Glanzmann's Thrombasthenia , 1974, British journal of haematology.

[25]  Oxon Dm.  Obituary. Rupert Samuel Bruce Pearson. , 1974 .

[26]  R. Zabel.  [Classification of hyperlipoproteinemias]. , 1974, Dermatologische Monatschrift.

[27]  G Bucolo,et al.  Quantitative determination of serum triglycerides by the use of enzymes. , 1973, Clinical chemistry.

[28]  L. Wilkins.  Classification of Hyperlipidemias and Hyperlipoproteinemias , 1972 .

[29]  S. Epstein,et al.  Impaired fibrinolytic response to exercise in patients with type-IV hyperlipoproteinaemia. , 1970, Lancet.

[30]  K. Huth.  [Classification of the hyperlipoproteinemias]. , 1970, Medizinische Klinik.

[31]  G. Born,et al.  The aggregation of blood platelets , 1963, The Journal of physiology.

[32]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[33]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[34]  L. Mannucci,et al.  Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  A. Henney,et al.  Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[36]  P. Winocour,et al.  Bezafibrate Retard in Patients with Insulin‐Dependent Diabetes: Effect on Serum Lipoproteins, Fibrinogen, and Glycemic Control , 1990, Journal of cardiovascular pharmacology.

[37]  M. Mancini,et al.  Measuring plasma fibrinogen to predict stroke and myocardial infarction. , 1990, Arteriosclerosis.

[38]  J. Vollmar,et al.  Diurnal lipid and lipoprotein profiles with bezafibrate and clofibrate in healthy volunteers. , 1985, Pharmatherapeutica.

[39]  A. Mantovani,et al.  Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. , 1985, The Journal of clinical investigation.

[40]  J. Wechsler,et al.  Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate. , 1983, Arzneimittel-Forschung.

[41]  E. Plow,et al.  The interaction of fibrinogen with human platelets in a plasma milieu. , 1982, Blood.

[42]  C. Sirtori,et al.  Platelet aggreation malondialdehyde formation in type IIA hypercholesterolemic patients. , 1979, Haemostasis.

[43]  P. Hekali,et al.  Serum lipids in angiographically assessed coronary atherosclerosis. , 1978, Chest.

[44]  P. Röschlau,et al.  Enzymatische Bestimmung des Gesamt-Cholesterins im Serum , 1974 .